Tech Company Financing Transactions
Protez Pharmaceuticals Funding Round
Protez Pharmaceuticals closed a $15 million Series B investment round on 9/24/2005. Investors included Birchmere Ventures and BioAdvance Ventures.
Transaction Overview
Company Name
Announced On
9/24/2005
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series B
Investors
Birchmere Ventures (Lead Investor)
BioAdvance Ventures (Sherrill Neff)
Proceeds Purpose
We look forward to using these funds to accelerate development of SMP-601, which we believe has significant potential to combat many of the lifethreatening infections that are taking an ever greater toll in lost lives and wasted resources.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
30 Spring Mill Drive
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Overview
Protez Pharmaceuticals discovers and develops new antibiotics for difficult-to-treat infections.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christopher Cashman
Chief Medical Officer
Clarence Young
Chief Scientific Officer
Luigi Xerri
Co-Founder
Klaus Esser
VP - R & D
Christopher Burns
Browse more venture capital transactions:
Prev: 9/23/2005: Sensory Analytics venture capital transaction
Next: 9/26/2005: Force10 Networks venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs